PLoS ONE (Jan 2010)

TDP-43-mediated neuron loss in vivo requires RNA-binding activity.

  • Aaron Voigt,
  • David Herholz,
  • Fabienne C Fiesel,
  • Kavita Kaur,
  • Daniel Müller,
  • Peter Karsten,
  • Stephanie S Weber,
  • Philipp J Kahle,
  • Till Marquardt,
  • Jörg B Schulz

DOI
https://doi.org/10.1371/journal.pone.0012247
Journal volume & issue
Vol. 5, no. 8
p. e12247

Abstract

Read online

Alteration and/or mutations of the ribonucleoprotein TDP-43 have been firmly linked to human neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). The relative impacts of TDP-43 alteration, mutation, or inherent protein function on neural integrity, however, remain less clear--a situation confounded by conflicting reports based on transient and/or random-insertion transgenic expression. We therefore performed a stringent comparative investigation of impacts of these TDP-43 modifications on neural integrity in vivo. To achieve this, we systematically screened ALS/FTLD-associated and synthetic TDP-43 isoforms via same-site gene insertion and neural expression in Drosophila; followed by transposon-based motor neuron-specific transgenesis in a chick vertebrate system. Using this bi-systemic approach we uncovered a requirement of inherent TDP-43 RNA-binding function--but not ALS/FTLD-linked mutation, mislocalization, or truncation--for TDP-43-mediated neurotoxicity in vivo.